In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback